Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
Intrinsic Value
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CERE.
Cerevel Therapeutics Holdings Inc's market capitalization is 7.6B USD.
CERE stock price is 42.14 USD.
CERE.
CERE. Open DCF Valuation
CERE. Open Relative Valuation
CERE has upside potential of 5% compared to the average analyst price target.
Open Wall St Estimates
CERE has negative Free Cash Flow for the last twelve months.
CERE's ROE (Return on Equity) has significantly decreased in the last 3 years from -59% to -72%, and is approaching profitability.
CERE has negative Operating Income for the last twelve months.
CERE has negative Net Income for the last twelve months.
CERE has negative Gross Profit for the last twelve months.
CERE's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -698% to -251%, and is approaching profitability.
CERE's long-term assets (1B USD) exceed its long-term liabilties (570m USD).
CERE's ROE (Return on Equity) for the past 12 months is negative and is equal to -72%.
CERE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -251%.
CERE's D/E (Debt to Equity) is very low and is equal to 0.5.
CERE has negative Net Debt. This means that the company has more cash and short-term investments (991m USD) than debt (337m USD).
CERE has negative three-year average ROE (Return on Equity): -71%. The company is not efficient at transforming stockholders' equity into net income.
CERE has negative three-year average ROIC (Return on Invested Capital): -378%. The company is not efficient at using invested capital to generate operating income.
CERE's short-term assets (1B USD) exceed its short-term liabilties (92m USD).
CERE's Altman Z-Score is very high and is equal to 5.26.
CERE doesn't generate enough operating income (-447m USD) to safely cover interest payments on its debt (9m USD).
Fundamental Analysis
Cerevel Therapeutics Holdings Inc
Balance Sheet Decomposition
Cerevel Therapeutics Holdings Inc
| Current Assets | 1B |
| Cash & Short-Term Investments | 991m |
| Receivables | 5.3m |
| Other Current Assets | 10.7m |
| Non-Current Assets | 236.4m |
| Long-Term Investments | 185.2m |
| PP&E | 45.8m |
| Other Non-Current Assets | 5.4m |
| Current Liabilities | 92.2m |
| Accounts Payable | 11.9m |
| Accrued Liabilities | 79.1m |
| Other Current Liabilities | 1.2m |
| Non-Current Liabilities | 477.4m |
| Long-Term Debt | 337.4m |
| Other Non-Current Liabilities | 140m |
Earnings Waterfall
Cerevel Therapeutics Holdings Inc
|
Revenue
|
0
USD
|
|
Cost of Revenue
|
-77m
USD
|
|
Gross Profit
|
-77m
USD
|
|
Operating Expenses
|
-370.3m
USD
|
|
Operating Income
|
-447.3m
USD
|
|
Other Expenses
|
14.4m
USD
|
|
Net Income
|
-432.8m
USD
|
Free Cash Flow Analysis
Cerevel Therapeutics Holdings Inc
What is Free Cash Flow?
CERE Profitability Score
Profitability Due Diligence
Cerevel Therapeutics Holdings Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Cerevel Therapeutics Holdings Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CERE Solvency Score
Solvency Due Diligence
Cerevel Therapeutics Holdings Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Cerevel Therapeutics Holdings Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CERE Price Targets Summary
Cerevel Therapeutics Holdings Inc
According to Wall Street analysts, the average 1-year price target for
CERE
is 44.27 USD
with a low forecast of 31.31 USD and a high forecast of 47.25 USD.
Ownership
CERE Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CERE Price
Cerevel Therapeutics Holdings Inc
| Average Annual Return | 45.94% |
| Standard Deviation of Annual Returns | 60.62% |
| Max Drawdown | -55% |
| Market Capitalization | 7.6B USD |
| Shares Outstanding | 181 580 000 |
| Percentage of Shares Shorted | 11.15% |
CERE News
Last Important Events
Cerevel Therapeutics Holdings Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Cerevel Therapeutics Holdings Inc
Company Profile
Cerevel Therapeutics Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2020-06-05. The firm combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The firm is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. The company is advancing diverse pipeline with numerous clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson's, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy. Its pipeline candidates include Emraclidine, Darigabat, Darigabat and CVL-871.
You don't have any saved screeners yet
